Banjak Marc 4
4 · iBio, Inc. · Filed Jan 30, 2026
Research Summary
AI-generated summary of this filing
iBio (IBIO) CLO Marc Banjak Receives Award of 146,000 Shares
What Happened
Marc Banjak, Chief Legal Officer of iBio, was granted a derivative award on Jan 28, 2026 covering 146,000 shares (reported as acquired at $0.00). The Form 4 lists this as an award/grant of derivative securities (transaction code A). The filing does not show any cash paid; this is a compensation equity award rather than an open‑market purchase or sale.
Key Details
- Transaction date: 2026-01-28 (Form 4 filed 2026-01-30; appears timely).
- Transaction type/code: Award/Grant (A) of derivative securities (options/rights) for 146,000 shares; acquisition price on form: $0.00.
- Shares owned after transaction: Not disclosed in the filing.
- Footnote (vesting): 25% vests on the one‑year anniversary of the grant; the remaining 75% vests in equal quarterly installments over the next 36 months, contingent on continued employment.
- No indication of immediate exercise or sale of underlying shares in this filing.
Context
This filing reports an equity compensation grant (an award of derivative securities) rather than a market trade. Such grants are typically part of executive compensation and do not by themselves indicate buying or selling in the market. The $0.00 figure reflects the reporting of the award on the Form 4 and does not represent market value realized by the insider.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-01-28+146,000→ 146,000 totalExercise: $2.23From: 2027-01-28Exp: 2036-01-27→ Common Stock (146,000 underlying)
Footnotes (1)
- [F1]These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.